(XRAY) Dentsply Sirona - Ratings and Ratios
Dental Equipment, Imaging Devices, Orthodontic Aligners, Implants, Catheters
Dividends
| Dividend Yield | 5.53% |
| Yield on Cost 5y | 1.35% |
| Yield CAGR 5y | 12.47% |
| Payout Consistency | 92.0% |
| Payout Ratio | 40.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 35.4% |
| Value at Risk 5%th | 52.3% |
| Relative Tail Risk | -10.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.08 |
| Alpha | -53.71 |
| CAGR/Max DD | -0.35 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.633 |
| Beta | 1.091 |
| Beta Downside | 0.836 |
| Drawdowns 3y | |
|---|---|
| Max DD | 74.96% |
| Mean DD | 35.25% |
| Median DD | 35.12% |
Description: XRAY Dentsply Sirona November 09, 2025
Dentsply Sirona (NASDAQ: XRAY) is a global dental-technology company that designs, manufactures and markets a broad portfolio of equipment, consumables and cloud-enabled software across four segments: Connected Technology Solutions (imaging, intra-oral scanners, 3-D printers and the CEREC chair-side restoration system); Essential Dental Solutions (endodontic handpieces, restorative materials, curing lights and prophylaxis products); Orthodontic and Implant Solutions (SureSmile clear aligners, digital denture platforms, implant components and treatment-planning software); and Wellspect Healthcare (urinary catheters and irrigation systems). The firm traces its roots to 1877 and is headquartered in Charlotte, North Carolina.
Key recent metrics show FY 2023 revenue of roughly $5.6 billion, an operating margin of about 13 %, and adjusted earnings per share of $4.20, driven largely by double-digit growth in its digital-dentistry and orthodontics lines. The primary economic drivers for XRAY are the aging U.S. and global populations, expanding dental insurance coverage, and the ongoing shift toward high-margin, technology-enabled workflows such as CAD/CAM and 3-D printing, which have been out-performing traditional consumable segments in the health-care supplies sub-industry.
For a deeper quantitative assessment, you may find ValueRay’s detailed valuation models for XRAY worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-882.0m TTM) > 0 and > 6% of Revenue (6% = 217.4m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -4.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.41% (prev 9.72%; Δ 8.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 221.0m > Net Income -882.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (199.5m) change vs 12m ago -0.75% (target <= -2.0% for YES) |
| Gross Margin 50.86% (prev 52.15%; Δ -1.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.03% (prev 58.86%; Δ 0.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.87 (EBITDA TTM -432.0m / Interest Expense TTM 79.0m) >= 6 (WARN >= 3) |
Altman Z'' -1.40
| (A) 0.12 = (Total Current Assets 2.07b - Total Current Liabilities 1.41b) / Total Assets 5.65b |
| (B) -0.25 = Retained Earnings (Balance) -1.39b / Total Assets 5.65b |
| (C) -0.13 = EBIT TTM -780.0m / Avg Total Assets 6.14b |
| (D) -0.49 = Book Value of Equity -2.05b / Total Liabilities 4.17b |
| Total Rating: -1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.54
| 1. Piotroski 2.50pt |
| 2. FCF Yield 1.85% |
| 3. FCF Margin 2.21% |
| 4. Debt/Equity 1.68 |
| 5. Debt/Ebitda -4.90 |
| 6. ROIC - WACC (= -24.81)% |
| 7. RoE -47.74% |
| 8. Rev. Trend -72.60% |
| 9. EPS Trend -54.55% |
What is the price of XRAY shares?
Over the past week, the price has changed by +2.84%, over one month by +6.73%, over three months by -13.37% and over the past year by -39.71%.
Is XRAY a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 13
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the XRAY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | 12% |
| Analysts Target Price | 13 | 12% |
| ValueRay Target Price | 9.3 | -19.3% |
XRAY Fundamental Data Overview December 10, 2025
P/E Forward = 6.5746
P/S = 0.6112
P/B = 1.5189
P/EG = 0.6575
Beta = 1.017
Revenue TTM = 3.62b USD
EBIT TTM = -780.0m USD
EBITDA TTM = -432.0m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 378.0m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.12b USD (from netDebt column, last quarter)
Enterprise Value = 4.33b USD (2.22b + Debt 2.48b - CCE 363.0m)
Interest Coverage Ratio = -9.87 (Ebit TTM -780.0m / Interest Expense TTM 79.0m)
FCF Yield = 1.85% (FCF TTM 80.0m / Enterprise Value 4.33b)
FCF Margin = 2.21% (FCF TTM 80.0m / Revenue TTM 3.62b)
Net Margin = -24.34% (Net Income TTM -882.0m / Revenue TTM 3.62b)
Gross Margin = 50.86% ((Revenue TTM 3.62b - Cost of Revenue TTM 1.78b) / Revenue TTM)
Gross Margin QoQ = 48.78% (prev 52.35%)
Tobins Q-Ratio = 0.77 (Enterprise Value 4.33b / Total Assets 5.65b)
Interest Expense / Debt = 0.93% (Interest Expense 23.0m / Debt 2.48b)
Taxrate = -86.09% (out of range, set to none) (198.0m / -230.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.47 (Total Current Assets 2.07b / Total Current Liabilities 1.41b)
Debt / Equity = 1.68 (Debt 2.48b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -4.90 (negative EBITDA) (Net Debt 2.12b / EBITDA -432.0m)
Debt / FCF = 26.46 (Net Debt 2.12b / FCF TTM 80.0m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -15.60% (Net Income -882.0m / Total Assets 5.65b)
RoE = -47.74% (Net Income TTM -882.0m / Total Stockholder Equity 1.85b)
RoCE = -20.18% (EBIT -780.0m / Capital Employed (Equity 1.85b + L.T.Debt 2.02b))
RoIC = -20.08% (negative operating profit) (EBIT -780.0m / (Assets 5.65b - Curr.Liab 1.41b - Cash 363.0m))
WACC = 4.73% (E(2.22b)/V(4.70b) * Re(10.03%) + (debt cost/tax rate unavailable))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.74%
[DCF Debug] Terminal Value 64.30% ; FCFE base≈194.0m ; Y1≈139.1m ; Y5≈75.9m
Fair Price DCF = 5.38 (DCF Value 1.07b / Shares Outstanding 199.6m; 5y FCF grow -33.29% → 3.0% )
EPS Correlation: -54.55 | EPS CAGR: -17.47% | SUE: -0.94 | # QB: 0
Revenue Correlation: -72.60 | Revenue CAGR: -4.82% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=-0.072 | Revisions Net=-5 | Analysts=11
EPS next Year (2026-12-31): EPS=1.58 | Chg30d=-0.441 | Revisions Net=-12 | Growth EPS=-2.1% | Growth Revenue=+0.7%
Additional Sources for XRAY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle